Relmada Therapeutics (RLMD) Tops Q4 EPS by 5c

Relmada Therapeutics (NASDAQ: RLMD) reported Q4 EPS of ($1.28), $0.05 better than the analyst estimate of ($1.33).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Norwegian Cruise Line Holdings (NYSE: NCLH) PT Raised to $20 at UBS
• Enhanced Group plans AI health platform launch in 2026
• Hesai Group (HSAI) Tops Q1 EPS by 8c